Telaprevir-d4
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Telaprevir-d4
Description :
Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].Product Name Alternative :
VX-950-d4UNSPSC :
12352005Target :
HCV; HCV Protease; Isotope-Labeled Compounds; SARS-CoVType :
Isotope-Labeled CompoundsRelated Pathways :
Anti-infection; Metabolic Enzyme/Protease; OthersField of Research :
InfectionSolubility :
10 mM in DMSOSmiles :
O=C(NC1C([2H])([2H])C1([2H])[2H])C([C@H](CCC)NC([C@@H]2[C@]3([H])[C@](CCC3)([H])CN2C([C@H](C(C)(C)C)NC([C@H](C4CCCCC4)NC(C5=NC=CN=C5)=O)=O)=O)=O)=OMolecular Formula :
C36H49D4N7O6Molecular Weight :
683.87References & Citations :
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Lin K, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother. 2006 May;50 (5) :1813-22.|[3]Perni RB, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006 Mar;50 (3) :899-909.|[4]Zhang X, et al. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. Eur J Med Chem. 2018 Jan 1;143:1053-1065.|[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.Shipping Conditions :
Room temperatureScientific Category :
Isotope-Labeled CompoundsClinical Information :
No Development Reported

